--(BUSINESS WIRE)--**SOLUTIONS FOR EVERY CHALLENGE IN OCULAR DRUG AND OPHTHALMIC MEDICAL DEVICE DEVELOPMENT**
Not just an ophthalmology-focused CRO, Iris Pharma helps clients around the world navigate every stage of the drug and device development process and delivers customized solutions.
CUSTOMIZED SOLUTIONS: ① Assessing possible therapeutic effect in ocular diseases; ② Adding value to promising drug candidates or medical devices; ③ Designing development plans and preclinical packages and carrying out studies to proceed with confidence from bench to bedside; ④ Providing a comprehensive clinical development services, from First-in-Human through Phase IV and Post-marketing follow-through. IRIS PHARMA'S A LA CARTE SERVICES: ① In vivo screening; ② Proof of concept studies; ③ Ocular efficacy studies; ④ GLP preclinical studies; ⑤ Bioanalytical testing services; ⑥ Clinical trials and clinical research services; ⑦ Post marketing surveys. ASSETS: ① 30 years of experience in the field of ophthalmology research; ② All ophthalmic indications mastered; ③ 70 FDA, PMDA & EMA new ocular drug approvals and ophthalmic medical device marketing authorizations; ④ State-of-the-art medical and scientific equipment; ⑤ Highly specialized and qualified staff; ⑥ Compliance with GLP, ICH-GCP and GCLP requirements; ⑦ CIR agreement.
|Headquarters Address:||Allée Hector Pintus|
|La Gaude 06610|
|Type of Organization:||Private|
|Industry:||Research & Science|
|Key Executives:||President: Yann Quentric|
|Contact:||Katia de Cuyper Barcaroli|